Meet our Board of Directors

Antibe’s Board of Directors comprises experts in corporate governance, growth financing, financial control, risk management, pharmacology, pharmaceutical development and large pharma transactions. All Directors are investors in the Company. Learn about Antibe’s corporate governance practices

Vice Chairman (retired)  Mastercard Incorporated, USA

Formerly a senior executive in global banking, Walt is a director of numerous private, public, and charitable endeavors.

Until 2020, he was Vice Chairman of MasterCard Incorporated, where he was involved in various public-private partnership initiatives. He previously served as President of International Markets, overseeing MasterCard’s business in 210 countries.


MBA  Schulich School of Business, York University, Canada
BA, BEd  Queen’s University, Canada

Walt is the founder of Mastercard’s Center for Inclusive Growth, and has chaired the Centre for Social Impact at Queen’s University, and Convergence Finance. He has been a board member of Save the Children Canada, Big Brothers Big Sisters of Canada, the Royal Conservatory of Music, and the Sunnybrook Hospital Foundation.

“Better medicines for pain promise a better world for billions of people.”

Emeritus Professor, Pharmacology  William Harvey Research Institute, Queen Mary University, UK

Rod has spent much of his career researching inflammation and anti-inflammatory drugs. He was a member of the original group that demonstrated the mechanism of action of NSAIDs. He has also made significant advances in understanding how the glucocorticoids and cromone drugs produce their anti-inflammatory and anti-allergic actions.

He is the former President of the British Pharmacological Society. Rod has published more than 350 papers and is a co-author of a best-selling pharmacology textbook.


PhD Pharmacology  University of London, UK
  University of London, UK
Honorary DSc
  University of Sheffield, UK
Honorary LLD (Doctor of Laws) 
University of Bath, UK

Academy of Medical Sciences, UK
British Pharmacological Society
Royal Society of Biology, UK
Royal Society of London, UK

Rod is a recipient of several awards, including the William Withering Prize of the Royal College of Physicians, the Wellcome Gold Medal of the British Pharmacological Society, and the Lifetime Achievement Award of the International Association of Inflammation Societies.

“I believe that Antibe has made a landmark advance towards a safer treatment for inflammation.”

Former CFO  Heron Therapeutics, USA
Director  Public biotechnology companies

In his most recent role, Robert was CFO of San Diego-based Heron Pharmaceuticals, a NASDAQ-listed commercial stage drug developer with a pipeline of acute pain therapeutics. During his tenure at Heron, the company raised more than $650 million and launched its second commercial drug product.

His career in the biotechnology sector began in 1997 at Arena Pharmaceuticals, where he rose to become CFO, holding that position for ten years. While at Arena, he was involved with its IPO and financings raising more than $1.5 billion. Robert is a member of the boards of three NASDAQ-listed pharmaceutical companies: Kura Oncology, Kintara Therapeutics (as Chairman) and ASLAN Pharmaceuticals.

BBA  St. Bonaventure University, USA

Member  Small Business Advisory Committee, Financial Accounting Standards Board (FASB).

Robert is a founding board member of Day for Change, which has funded charities serving underprivileged and abused children in the San Diego area for 20 years.

“It’s a great time to work with Antibe’s impressive team to capture the full potential of a uniquely promising drug pipeline and platform.”

Chief Business Officer  Knight Therapeutics, Canada

Amal is a senior pharmaceutical business development and licensing executive. She is Chief Business Officer for Knight Therapeutics, a company focused on in-licensing innovative, late-stage products for Canada and select international markets.

At Novartis Pharma AG, she held roles of Head of Partnering for General Medicines and Mature Products, Business Expansion Molecular Diagnostics, and Search and Evaluation IHC/Ophtha Franchises.


MBA  University of Ottawa, Canada
BSc Biochemistry  McGill University, Canada\

Amal has led due diligence, deal structuring and negotiations for more than 20 transactions, with a combined deal value of $500M.

“The treatment of pain continues to pose a great challenge as there is a high unmet need for safe and effective pain therapies.”

Having first met him in university, Antibe’s founder, John Wallace, reconnected with Dan nearly 30 years later, seeking to tap his talent for leading senior teams in building best-in-class ventures.

Trained as a corporate lawyer and as an air force rescue pilot, Dan’s career has evolved to focus on high-growth, mostly technology-based companies. His CEO-level experience includes organizations specializing in data analytics, IT and consumer marketing.

He has served on the boards of directors of International Save the Children and of Green Shield Canada, a leading health benefits administrator. Dan continues to serve as a board member and advisor to several companies and not-for-profit organizations.


JD   Queen’s University, Canada

Law Society of Upper Canada
New York State Bar, USA

Dan’s leadership experience began with eight years as a military pilot, principally as an air rescue captain.

“We think we’ve solved one of the significant, long-standing medical problems of our time.”

Chief Financial Officer  Codex DNA, USA

Jennifer is a senior financial and strategy executive with a considerable breadth of experience in the biotechnology sector, as an analyst, portfolio manager, information provider and expert in corporate communications and investor relations.

She began her career as a healthcare equity analyst, transitioning to management of biopharmaceutical-focused investment funds. She subsequently founded Laurient LLC, an independent equity research and competitive intelligence platform analyzing publicly traded biopharmaceutical companies. Since 2013, Jennifer has served on the board of Enzon Pharmaceuticals.

Master of Health Administration (MHA)  Cornell University, USA
BA  Cornell University, USA

Jennifer managed biopharmaceutical-focused investment funds for Morgan Stanley Dean Witter Advisors, Amerindo Investment Advisors and latterly at Franklin Templeton, where she co-managed the Franklin Biotechnology Discovery Fund.

“The severe shortcomings of today’s pain medications constitute one of the world’s most pressing medical needs. Patients deserve better. Antibe’s novel drug platform is a promising way forward – I am delighted to be a part of it.”

John is widely recognized as an expert in gastrointestinal inflammation and in the development of innovative anti-inflammatory medicines. In the mid-1990s, he co-founded NicOx and chaired its Scientific Advisory Board. (NicOx was the first company to achieve regulatory approval for drugs using gasotransmitters.)

John and his research colleagues are credited with identifying one of the main mechanisms of damage to the stomach by NSAIDs. More recently, he was the first to uncover hydrogen sulfide’s anti-inflammatory properties, leading to the formation of Antibe Therapeutics.

He is Founding Director of the Farncombe Family Digestive Health Research Institute at McMaster University and former President of the Canadian Association of Gastroenterology.


PhD Medical Science  University of Toronto, Canada
Postdoctoral studies at Wellcome Research Laboratories, UK
MBA  University of Birmingham, UK

Brazilian Academy of Science
British Pharmacological Society
Royal Society of Canada

Adj. Professor, Physiology and Pharmacology  University of Calgary, Canada
Adj. Professor, Pharmacology and Toxicology  University of Toronto, Canada

John received the Premier’s Summit Award in Innovation in 2009, financially the largest prize awarded to an individual scientist in Canada. He is also the recipient of the 2011 William Harvey Medal from the William Harvey Institute in London, UK. John was awarded the Heymans Foundation Medal in 2013—one of only twelve scientists so honored since the foundation was established nearly 50 years ago.

As research delivers new insights into the deep biology of hydrogen sulfide, we are widening our exploration of its therapeutic potential.”

CEO  MaRS Discovery District, Canada
Director  Toronto Region Board of Trade, Canada

Yung has built breakthrough companies in mobile analytics and big data, media and entertainment, enterprise software, financial services and pharma. He is CEO of the MaRS Discovery District, the largest urban innovation hub in North America, and Canada’s premiere science and technology innovation ecosystem. In the last 12 months, MaRS’s 1,200 start-ups collectively employed over 13,000 people, generated $1.4B in net revenues and raised over $1.3B in capital.

He serves on the board directors of OMERS, a leading Canadian institutional investor with $100 billion under management. Yung is a former director of Green Shield Canada, a leading health benefits administrator and one of Canada’s foremost social enterprises in healthcare.


Entrepreneurial Masters Program  Massachusetts Institute of Technology, USA
BSc Computer Science, Economics and Mathematics  University of Toronto, Canada

Directors Education Program  Rotman School of Management, University of Toronto, Canada

Certified Management Consultant 
Canadian Assoc. of Management Consultants
Certified Corporate Director (ICD.D)  Institute of Corporate Directors, Canada

Yung was recognized as one of Canada’s “Top 40 under 40” leaders earlier in his career and as chief executive of one of Canada’s “50 Best Managed Private Companies”.

“Antibe ranks amongst the most promising biotech companies that we work with.”


  1.  Audit Committee
  2.  HR and Compensation Committee
  3.  Corporate Governance Committee


This is an external link. Click “OK” to continue.